Comprehensive Analysis of Emerging Strategies for Targeting Cyclin-Dependent Kinases in Cancer

More than 30 years after the direct connection was established between the molecular machinery controlling cell division and cancer, a new paper traces the evolution of cyclin-dependent kinase research and outlines the next generation of CDK-targeted therapies.

Published in Molecular Medicine, the article, "Cyclin/CDK inhibition in cancer therapy: from small molecules and macrocycles to advanced drug delivery systems," provides a comprehensive analysis of established and emerging strategies for targeting cyclin-dependent kinases, or CDKs.

CDKs are enzymes that regulate cell-cycle progression, but their biological influence extends well beyond cell division. They also participate in gene transcription, DNA-damage responses, DNA repair, metabolism, immune regulation and cellular senescence. Their dysregulation is a defining feature of many malignancies, making them important, but highly complex therapeutic targets.

A Scientific Journey Beginning in 1989

The new publication carries particular historical significance for its senior and co-corresponding author, Antonio Giordano, M.D., Ph.D., Founder and Director of the Sbarro Health Research Organization (SHRO) and Professor at Temple University.

In 1989, Giordano was the first author of a landmark study published in Cell that provided one of the earliest direct experimental links between the cyclin/CDK machinery and oncogenic transformation. The researchers demonstrated that a cdc2-associated protein complex interacted with the adenovirus E1A oncoprotein in infected and transformed human cells. The p60 component of that complex was subsequently identified as cyclin A.

Five years later, in 1994, Giordano's laboratory at Temple University identified a previously unknown nuclear kinase, initially named PITALRE and now recognized as CDK9. The original study, published in the Proceedings of the National Academy of Sciences, showed that PITALRE was associated with kinase activity directed against the retinoblastoma protein.

CDK9 has since emerged as a crucial regulator of transcription, DNA-damage responses and cancer-cell survival, as well as an increasingly important target for anticancer therapy.

This review closes a scientific circle that began for me in 1989, when we helped demonstrate that the machinery controlling normal cell division could be directly connected to oncogenic transformation, and continued in 1994 with the identification of PITALRE, the kinase now known as CDK9."

Antonio Giordano, Director, Sbarro Institute for Cancer Research and Molecular Medicine

"Today, we understand that cyclin-dependent kinases are not merely molecular switches driving cell proliferation. They are central regulatory hubs connecting cell division with gene transcription, DNA repair, metabolism, immune responses and cellular senescence. CDK9, in particular, stands at the intersection of transcription, genome stability and cancer-cell survival," Giordano concludes. 

Beyond Conventional CDK Inhibition

Several small-molecule CDK inhibitors have already been approved for cancer treatment, particularly drugs targeting CDK4 and CDK6. However, their broader clinical application can be limited by acquired resistance, insufficient selectivity, poor solubility, suboptimal biodistribution and toxicity resulting from exposure of healthy tissues.

The new review focuses particularly on CDK4/6 and CDK9, the most clinically advanced examples of CDK targeting, as well as the emerging, context-dependent role of CDK10 in cancer progression and resistance to endocrine therapy.

The authors analyze multiple mechanisms through which tumors can escape CDK-targeted treatment. These include loss or inactivation of the retinoblastoma protein, activation of alternative cyclin-CDK pathways, increased CDK2 activity, adaptive oncogenic signaling, metabolic reprogramming and transcriptional recovery.

The review identifies three major areas that could shape the future of CDK-targeted oncology:

Macrocycles: These ring-shaped molecules can interact with large and complex protein surfaces that are often inaccessible to conventional small molecules. Macrocycles may therefore disrupt interactions between cyclins and CDKs with greater selectivity. Their development must still overcome challenges involving synthesis, membrane permeability and bioavailability.

Targeted protein degradation: PROTACs and molecular glues are designed not simply to inhibit CDKs but to recruit the cell's protein-disposal machinery and eliminate them. This approach may produce more durable biological effects and help overcome certain forms of resistance to conventional inhibitors.

Advanced drug-delivery systems: Liposomes, polymeric nanoparticles, micelles, nanosponges, hydrogels and engineered extracellular vesicles may protect drugs from premature degradation, improve solubility and controlled release, and increase their accumulation within tumors while reducing systemic exposure.

"The next step is not simply to produce more powerful inhibitors, but to achieve smarter inhibition," adds Giordano. "We must select the appropriate CDK target, understand and anticipate resistance, and deliver the drug precisely where it is needed. The convergence of small molecules, macrocycles, targeted protein degradation and advanced drug-delivery systems gives us an important opportunity to attack tumor biology with greater precision while limiting damage to healthy tissues."

From Laboratory Innovation to Patient Benefit

The authors emphasize that drug-delivery technologies should not be regarded as universal solutions. Each delivery platform must be selected according to the chemical properties of the individual inhibitor, the biology of the tumor and the specific therapeutic objective.

The review examines delivery strategies under investigation for CDK inhibitors including abemaciclib, ribociclib, alvocidib, seliciclib and dinaciclib.

Before these approaches can enter widespread clinical use, they will require rigorous comparisons with the corresponding free drugs, quantitative biodistribution studies, validation in appropriate in vivo models and careful assessment of efficacy and toxicity. Manufacturing scalability, reproducibility, storage stability and regulatory compliance will also be essential.

"Translating this scientific potential into tangible benefits for patients will require rigorous validation, multidisciplinary collaboration and a continuous bridge between molecular discovery and clinical application," Giordano says. "This is the path toward a new generation of more precise, effective and personalized cancer therapies."

The publication integrates current preclinical and clinical evidence, identifies unresolved challenges and proposes priorities for the future development of CDK-targeted treatments.

International Collaboration

The review brings together researchers affiliated with the Sbarro Institute for Cancer Research and Molecular Medicine, at the Center for Biotechnology, College of Science and Technology, Temple University, the University of Siena, the University of Naples Federico II, the Scuola Superiore Meridionale, and the Istituto Nazionale Tumori IRCCS Fondazione G. Pascale.

Simone Braccia and Giulio Mazzarotti contributed equally to the work. Luigi Alfano and Antonio Giordano are the corresponding authors.